Vitiligo is a chronic skin condition in which patches of skin lose their color, turning white or significantly lighter than the surrounding area. It affects roughly 0.5% to 2% of the global population and can appear at any age, though it most often begins before age 30. The condition is not contagious, not painful, and not dangerous on its own, but it can have a significant emotional impact and sometimes signals other autoimmune conditions happening beneath the surface.
What Vitiligo Looks Like
Vitiligo appears as flat, white or milky patches on the skin where pigment-producing cells have been destroyed. The patches have well-defined edges and can range from a few millimeters to several centimeters across. They tend to show up first on the face, hands, arms, feet, and around body openings like the lips and genitals. Skin creases and areas that experience friction or sun exposure are also common starting points.
The patches themselves are painless and typically don’t itch. In some people, the hair growing within an affected patch also turns white, including eyebrows, eyelashes, and beard hair. On lighter skin tones, vitiligo can be subtle until the surrounding skin tans. On darker skin tones, the contrast is more visible and often noticed earlier.
Doctors can confirm the diagnosis using a Wood’s lamp, a handheld ultraviolet light. Under this light, vitiligo patches glow a bright blue-white, making them easy to distinguish from other causes of light skin patches, especially in people with fair complexions where the color difference might be hard to see with the naked eye.
Why It Happens
Vitiligo is fundamentally a case of the immune system turning against the body’s own melanocytes, the cells responsible for producing skin pigment. The process unfolds in stages. First, melanocytes come under stress, often from a buildup of harmful molecules called reactive oxygen species. These molecules damage the internal machinery of melanocytes, particularly their mitochondria (the cell’s energy centers) and their protein-folding systems. Under that stress, melanocytes begin releasing distress signals into the surrounding tissue.
Those distress signals act like alarm bells. Nearby skin cells respond by recruiting immune cells to the area. In a healthy immune response, this would clear a genuine threat and settle down. In vitiligo, the immune system misidentifies the melanocytes themselves as the threat. A specific type of immune cell, called a CD8+ T cell, moves in and directly kills the melanocytes using the same tools it would use against an infected cell. The melanocytes are destroyed, pigment production stops, and the skin turns white.
The adhesion between melanocytes and their neighboring skin cells also weakens under stress, meaning some melanocytes may simply detach from the skin before the immune system even reaches them. Once the melanocytes in a given patch are gone, pigment cannot be produced there unless new melanocytes migrate in from hair follicles or surrounding skin, which is why repigmentation, when it happens, often appears as tiny dots around hair follicles first.
Genetics and Triggers
Vitiligo has a strong genetic component. Researchers have identified roughly 50 gene regions that contribute to risk. Many of these genes govern how the immune system recognizes threats and regulates itself, which explains why the condition clusters with other autoimmune diseases. Other implicated genes are directly involved in melanocyte function and pigment production.
Having a family member with vitiligo raises your risk, but genetics alone don’t determine whether you’ll develop it. Environmental triggers typically set the process in motion. Sunburn and skin trauma are among the most common. This phenomenon, called Koebnerization, means vitiligo patches can appear at the exact site of a cut, scrape, or burn. Emotional stress, chemical exposure (especially to certain industrial compounds), and hormonal changes have also been reported as triggers, though their roles are harder to pin down.
Two Main Types
Vitiligo is classified into two main forms, and they behave quite differently.
Non-segmental vitiligo is far more common. Patches tend to appear symmetrically on both sides of the body (both hands, both knees, for instance) and spread gradually over time. This form can continue expanding for years or decades, with periods of stability interrupted by new patches.
Segmental vitiligo is less common and typically appears on only one side of the body in a band-like pattern. It tends to start quickly, spreading within its segment over 6 to 24 months, and then stops. Hair in the affected area often turns white early. Because it stabilizes relatively fast, segmental vitiligo is generally more predictable and responds well to certain treatments.
Linked Autoimmune Conditions
Because vitiligo involves immune system dysfunction, it frequently overlaps with other autoimmune conditions. Thyroid disease is the most common companion, affecting about 14% of people with vitiligo. Hypothyroidism (underactive thyroid) accounts for most of those cases. Psoriasis co-occurs in about 5% of vitiligo patients, and rheumatoid arthritis in roughly 3%.
Alopecia areata (patchy hair loss), type 1 diabetes, and pernicious anemia also appear more frequently in people with vitiligo than in the general population. The more extensive the vitiligo, the higher the likelihood of having one of these conditions alongside it. This is why many dermatologists will order blood work to check thyroid function and screen for other autoimmune markers after a vitiligo diagnosis.
Treatment Options
Vitiligo treatment focuses on restoring pigment to affected areas, stabilizing the condition to prevent further spread, or both. Results vary widely depending on the location of patches (facial skin responds best), the type of vitiligo, and how long the patches have been present.
Phototherapy
Narrowband UVB phototherapy remains one of the most effective and widely used treatments. Sessions are ideally done three times per week for the best results, though twice weekly is common for practical reasons. The treatment requires patience. It typically takes 18 to 36 sessions before any visible response, and a minimum of six months before you can fairly judge whether it’s working. If there’s no improvement after 48 sessions, the treatment is generally considered unsuccessful for that patient.
When phototherapy does work, repigmentation usually begins as small brown dots around hair follicles within the white patches, which gradually expand and merge.
Topical and Oral Medications
Topical ruxolitinib cream is the first treatment specifically approved for vitiligo. It works by blocking signals that drive the immune attack on melanocytes and has shown the most consistent results on facial patches. It’s approved for both adolescents and adults.
Several oral medications in the same drug class are in advanced clinical trials or being used off-label. These include ritlecitinib, upadacitinib, and povorcitinib. Early results suggest they work best when combined with phototherapy rather than used alone. Topical corticosteroids and calcineurin inhibitors are also commonly prescribed, especially for limited patches.
Emotional and Social Impact
Vitiligo is often described as a “cosmetic” condition, but that label understates the psychological burden many people carry. In clinical studies, about one in four vitiligo patients shows significant mental health strain, and roughly 13% report that the condition substantially impairs their day-to-day quality of life. The emotional toll correlates directly with how much of the body is affected and how visible the patches are.
Social functioning takes a particular hit. People with more extensive vitiligo score notably lower on measures of social well-being, reporting self-consciousness about their appearance in work settings, social gatherings, and intimate relationships. In one study, 11% of patients said they would be willing to spend more than 40% of their monthly income for a complete cure, a striking measure of how much the condition weighs on people even when it causes no physical pain.